Panbela Therapeutics Inc. (NASDAQ: PBLA) closed the day trading at $1.11 down -9.76% from the previous closing price of $1.23. In other words, the price has decreased by -$0.1200 from its previous closing price. On the day, 844559 shares were traded.
Ratios:
For a better understanding of PBLA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.21 and its Current Ratio is at 0.21.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 08 ’23 when GOLDMAN SACHS GROUP INC sold 72,874 shares for $0.71 per share. The transaction valued at 51,741 led to the insider holds 397,954 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBLA now has a Market Capitalization of 4.35M and an Enterprise Value of 8.64M.
Stock Price History:
Over the past 52 weeks, PBLA has reached a high of $556.80, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is 6.4974, while the 200-Day Moving Average is calculated to be 35.3624.
Shares Statistics:
Over the past 3-months, PBLA traded about 887.44K shares per day on average, while over the past 10 days, PBLA traded about 373.65k shares per day. Insiders hold about 0.02% of the company’s shares, while institutions hold 0.16% stake in the company. Shares short for PBLA as of Feb 15, 2024 were 106.97k with a Short Ratio of 0.12, compared to 46.36k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.07% and a Short% of Float of 3.07%.
Earnings Estimates
Current recommendations for the stock of the company come from 2 analysts. On average, analysts expect EPS of -$24.34 for the current quarter, with a high estimate of -$20.28 and a low estimate of -$28.4, while EPS last year was -$3,408. The consensus estimate for the next quarter is -$1.48, with high estimates of -$1.48 and low estimates of -$1.48.
Analysts are recommending an EPS of between -$194.6 and -$213.13 for the fiscal current year, implying an average EPS of -$203.86. EPS for the following year is -$34.38, with 2 analysts recommending between -$4.97 and -$63.8.
